Neurocrine Biosciences (NBIX) EPS (Basic) (QoQ) (2010 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EPS (Basic) (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.13 Bn | 625.38 Bn | 17.26 Bn |
| 2 | AbbVie | 442.39 Bn | 435.82 Bn | 12.70 Bn |
| 3 | Merck | 366.26 Bn | 359.12 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn |
| 5 | Pfizer | 159.00 Bn | 147.30 Bn | 10.94 Bn |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 8 | Incyte | 25.41 Bn | 20.87 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.59 Bn | 15.20 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.40% |
| Mar 31, 2026 | 27.48% |
| Dec 31, 2025 | -26.71% |
| Sep 30, 2025 | 94.10% |
| Jun 30, 2025 | 1,270.38% |
| Mar 31, 2025 | -92.28% |
| Dec 31, 2024 | -20.02% |
| Sep 30, 2024 | 99.10% |
| Jun 30, 2024 | 48.28% |
| Mar 31, 2024 | -71.23% |
| Dec 31, 2023 | 78.10% |
| Sep 30, 2023 | -13.25% |
| Jun 30, 2023 | 224.03% |
| Mar 31, 2023 | -184.92% |
| Dec 31, 2022 | 29.93% |
| Sep 30, 2022 | 504.48% |
| Jun 30, 2022 | -221.20% |
| Mar 31, 2022 | 289.01% |
| Dec 31, 2021 | -132.48% |
| Sep 30, 2021 | -46.86% |